
Electric Vessev VS-9 Hydrofoil Is 5X More Efficient Than Regular Boats
Vessev's VS-9 has already started commercial service with Fullers360 in Auckland, New Zealand.
Most of the focus around electrifying transport has been on land-based vehicles. But water journeys can also benefit from more sustainable power – if you can find a way to increase efficiency. New Zealand-based Vessev reckons the combination of unique hydrofoil technology and electric motors can revolutionize small boats. I talked to CEO Eric Laakmann about the possibilities, while an on-location team took the Vessev VS-9 for a test ride at its home location of Auckland.
At first glance, the VS-9 looks like an ordinary boat, although the clean appearance has some resemblance to a modern technology device. This is no surprise when you learn that Laakmann brings to bear years of experience developing products at Apple, including later iPod generations, iPads and the original Apple Watch. After some years spent on a sailing sabbatical, he ended up in New Zealand, the home of modern hydrofoiling after the 2013 Americas Cup win empowered by the technology.
This was the original inspiration behind Vessev. 'The founder of the company Max looked at that and thought it could be commercialized,' says Laakmann. When he joined the company, he brought his product management knowledge to build a strategy and define which markets to chase. 'Two markets stood out to me as places to start with. One was harbor ferry operators because they have an intense usage of fuel. They turn on at 5:00 AM and off at 10:00 PM, using fuel the entire time, even idling at dock. We can cut that by up to 90%. That's an important cost saving when each boat uses cubic meters of fuel every day. The other market was tourism operators looking for ways to make their operation more sustainable.'
The VS-9 rides very smoothly once it has raised onto its hydrofoils.
The VS-9 brings together two innovations to create a compelling package – hydrofoiling and battery electrification. The former improves efficiency by lifting the boat out of the water so that it 'flies' over the surface, dramatically reducing drag, and the latter (like land-based EVs) makes for much more frugal energy usage. 'This combination is three to five times more efficient than what has come before and that's a big number,' says Laakmann. 'If you looked at automotive or aviation and said there's this new technology, it's going to make cars or planes 3 to 5 times more efficient, that would be a game changing innovation, and we have that for marine.'
In fact, the reduced drag of hydrofoiling is what makes electrification possible, because a very efficient powertrain is more sensitive to inefficiencies elsewhere. 'It's a synergy made in heaven, hydrofoiling and electrification, because anytime you electrify something, you must be responsible about how you're using the electricity. The weight of the battery is significantly more than fossil fuels in terms of energy. The VS-9's batteries are 98.6kWh, which is about the same as the Tesla Cybertruck or Rivian R1T.'
This battery size makes the VS-9 very practical. 'It's not any bigger than a car, so we can use Type 2 car chargers like on any vehicle without issue, which means we can charge in any marina with normal 22-kilowatt AC car chargers,' says Laakmann. The onsite reviewers in Auckland witnessed this in action, as the VS-9 was plugged into a standard Type 2 charger, having consumed roughly 18% of its battery for a 30-minute ride in the harbor. The fuel for this might have cost $83 in fossil fuel for a regular boat, but less than $5 of electricity for the VS-9. Assuming hydrofoil cruising, the VS-9 has a range of 50 miles with one passenger, dropping to 40 miles with the maximum 10 passengers. When foiling, energy consumption is around 2.5kWh per nautical mile.
The hydrofoiling is not complicated for the boat's pilot, as the transition is automatic. The foils are controlled by actuators and sensors of boat height and speed rather than operating manually. 'The boat takes off at 19 knots,' says Laakmann. 'That's when the foils have enough lift to get out of the water. It cruises between 20 and 25 knots. That's the most efficient. The top speed will be around 30 knots.' This makes for a non-uniform relationship between speed and efficiency. The drag on a hydrofoiling boat goes up until they lift out of the water, then it drops for a bit and then goes up a lot. 'There is a certain speed where you'll be as efficient as a certain slow speed. We're as efficient at 25 knots as we are at 5 knots on the VS-9.'
The test team (my intrepid relatives who live in Auckland) commented that it wasn't obvious that the VS-9 was transitioning from normal to foils because this was a gradual process, although once the change was complete the ride was clearly smoother, and you could see a smaller wake out the back of the boat. Turns were particularly slick, rapid and impressively stable. Overall, it felt smoother and faster than a regular ferry, although not as quiet as expected. Vessev's next design should reduce this considerably.
This is not my family in a Vessev VS-9 boat.
'The current motor is a bit loud,' says Laakmann. 'We've got a new propulsion system that we're putting in the water on July 1st. Our current boat uses an axial flux motor on top of the T foil that drives the struts down to a gearbox, which goes out to a prop. It is 90% efficient, but you're losing energy. With the new system, we're winding our own custom motors with steel magnets, copper and aluminum. This is direct drive on the hydrofoil itself with two of our own custom 40kW motors. Active cooling allows us to make the motors even smaller because the motors are in the water. That will be a big upgrade just in terms of efficiency, manufacturing, and noise. We expect greater efficiency and range.'
The VS-9 doesn't need expensive batteries with exotic chemistry, either. In fact, the Lithium Iron Phosphate (LFP) type popular in commercial electric vehicles such as buses and trucks is ideal. 'There's a lot of good reasons for that,' says Laakmann. 'LFP is cheaper. It doesn't have any nickel or manganese or cobalt. We had some considerations around how they're mined but the real important thing to us is LFP batteries are long-lasting even at deep discharges. If you look at road vehicles and how they're used, most of the time, you're probably only using a couple percent of the battery, because you're doing short runs and occasionally a long road trip.'
'For nickel manganese cobalt (NMC), every time you deeply discharge it, you're doing a lot of degradation to the battery cycle life,' continues Laakmann. 'With LFP you can deeply discharge over 80% or 4,000 cycles, which is much more aligned with what this commercial marine application scenario is. It's a little bit heavier of course, but if you're measuring the performance of your vehicle at Year 5 versus Year Zero, you end up with better performance with LFP batteries than NMC. We're not trying to make an F1 car or an America's Cup vessel. We're trying to make an SUV, pickup truck or minivan – something that is safe and just gets the job done.
The review team said the VS-9 looked relatively normal compared to other boats in the marina, with no obvious signs of the capabilities that lie below the waterline at rest. The interior is modern but not overly ostentatious, with a tidy control area. There is room to walk around in transit, and the windows are large enough to take pictures during the journey. My onsite team were impressed with the slickness of the VS9, considering it is the first boat from Vessev.
Since its unveiling last year, the VS-9 is already finding commercial interest, and the first vessel went into service in Auckland on January 29th, 2025. 'It's been going well,' says Laakmann. 'We've got the world's best partnership with the largest ferry operator in New Zealand, Fullers360. They've got a fleet of 4,966 seats. They've got a zero emissions goal by 2040 and were looking at the technology that gets us there.'
The Vessev VS-9 cruises at around 25 knots.
Laakmann sees a bright future for Vessev and other startups that have entered the electric hydrofoil market, such as Candela. 'Automotive is totally different to boat manufacturing,' he says. 'You probably have 20,000 different boat manufacturers in the world whereas automotive manufacturing is a mere handful of big companies.' Boat companies also tend to produce much more customized designs. 'The VS 9 platform is flat on the deck, so we can put whatever we want on top of it,' he says. 'We're doing a production run of 12 and they're going to be different configs. Some of them will be a water taxi configuration. Others will be much more geared towards recreational. Some will be workboats.'
He also envisages larger Vessev designs in the future. 'Most ferry operators are not looking for 10-passenger boats because that's much more of a tourism experience thing,' he says. 'They're looking for something bigger, so we're going to be scaling up to versions of these vessels that we're calling the VS-18 because it's nominally 18 meters long. It will be all the same tech, just bigger. The upper limit is 40 meters. The Boeing 929, which is a hydrofoil created by Boeing in 1975, is around 90 feet, or 27m. There is still a handful of those in operation in Hong Kong and Japan. These things can get quite big, but we don't want to start there.'
Although an 18m Vessev craft would be twice as long as the VS-9, it would still only have one deck so aerodynamic drag wouldn't increase proportionately. It would also enable the foils to be wider, which is more efficient. 'On this larger vessel, it'll have a much larger beam, a width of 10.5m, so it would be a high aspect ratio wing that should get us some significant additional efficiency gains,' says Laakmann.
Laakmann sees a very healthy potential market for Vessev. 'There are just over 100 electric hydrofoiling boats in the world today, but there are 33 million boats overall,' he says. 'Given that this is the most efficient way to move on the water at high speed, it's not crazy to think that there'll be a good number of vessels that do go this way. Even 1% would be 330,000. That's a lot of sales potential. The base VS-9 is $620,000, with options that come on top of that, but the running cost savings are huge. Some people in island resorts are considering orders of around 40 boats.'
Who knows, we could see a Vessev VS-9 in the next season of The White Lotus. 'I did watch the show recently and it did cross my mind,' concludes Laakmann.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
42 minutes ago
- Business Upturn
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]

Hypebeast
2 hours ago
- Hypebeast
HAVEN's Summer 2025 Collection Centers on the Pacific Northwest's Terrain
Vancouver-based labelHAVENhas unveiled a coastal campaign for its Summer 2025 collection, returning with a capsule of essentials designed for the warm days and cool nights of Summer in the Pacific Northwest. Utilizing cotton-linen gabardines, Japan denim, and lightweight Super 140s wool, the label offers a range of core garments characterized by the label's functional, minimalist ethos. HAVEN opts for a light and neutral color palette inspired by the woodland coast of Vancouver, led by tones of beige, sage green, brown, off-white, and indigo. The collection is anchored by matching linen gabardine sets, comprising a work jacket that reinterprets the classic military BDU (battle dress uniform) garments. Offered in a dark brown and beige colorway, the jacket's ergonomic tailoring and underarm gussets elevate the utilitarian design with contemporary elegance. In indigo and white, Japanese linen denim shirts and trousers offer a cooling feel and soft hand. The denim Helix Pant features twisted side seams for a sculpted fit and added mobility, and functional details, like slant hand pockets, storm welt back pockets, and snap-adjustable waist tabs. HAVEN tops the collection off with wool Summer shirting, including wool versions of the aforementioned denim shirts in beige, green, and brown checks. Utilizing Super 140s wool, known for its ultra-fine quality, the collection also offers short-sleeve camp collar shirts in the same three colorways. See the gallery above for a closer look at the campaign. HAVEN's Summer 2025 Delivery 1 is out now at the brand'swebsiteand physical store.
Yahoo
2 hours ago
- Yahoo
Valve does its homework the night before deadline: Switches Steam to run on Mac chips right as Apple announces it's ditching Intel for good
When you buy through links on our articles, Future and its syndication partners may earn a commission. I've said it before and I'll say it again: my 2020 MacBook Air is the best gaming laptop I've ever owned. Not because it can run anything I throw at it (it can't) or because it's some ungodly-powerful slab of RGB (it's not). But it runs everything I want it to run—Infinity Engine RPGs, KOTOR 1 and 2, things of that nature—silently and with battery life out the wazoo. It does that because it's one of the first bits of Apple kit to use the megacorp's own, bespoke ARM line of M-series CPUs, breaking a dependence on Intel chips going all the way back to 2006. Which is neat, but there was a problem—damn near every app out there is built to work on x86 chips like Intel's, and not ARM. Apple solved that little issue with a thing called Rosetta 2, which effectively translated x86 apps to ARM on the fly when you tried to run them on ARM-based Macs. But nothing gold can stay: at this year's WWDC, Apple quietly pointed out to devs that, two macOS generations from now, Rosetta would pretty much be going the way of the dodo. Devs would have to make their apps ARM-native or sling their hook. Which brings us to Steam. Valve being Valve—and macOS making up an absolutely infinitesimal percentage of overall Steam users—it never bothered to create an Apple Silicon-native version of Steam in all these past five years. Until yesterday. With Apple suddenly putting a time limit on how long devs could rely on Rosetta, Valve has gotten its act together and released an ARM version of Steam as part of yesterday's Steam client beta. Gotta be honest, it's very relatable. It reminds me of all the university essays I scrambled to write the night before they were due. I imagine Gabe sitting on his yacht, watching Apple's coiffed execs intro WWDC, suddenly sitting bolt upright as he realises they forgot to make Steam run on modern Macs. The Apple-native version of Steam is currently only available in beta, which you can swap to by heading to your preferences, then Interface, then selecting the beta version of Steam from a drop-down menu. It works well! In my very limited (10 minutes or so) of mucking about with it, I've had better luck getting the Steam Overlay to work and game recording seems to actually function now (albeit without game audio, because Apple makes it borderline impossible to record system audio on Macs for some reason) which wasn't the case last time I messed with those features—which was admittedly a few updates ago. Anyway, the perhaps dozens of people playing Steam games on Mac can heave a sigh of relief. For a minute there, I wondered if Valve would bother to update Steam for Apple Silicon at all. Macs are a tiny fragment of its audience and Apple Silicon users are a tiny fragment of that. I'm glad Gabe still cares enough about those of us who love overpaying for hardware to keep things in working order. 2025 games: This year's upcoming releasesBest PC games: Our all-time favoritesFree PC games: Freebie festBest FPS games: Finest gunplayBest RPGs: Grand adventuresBest co-op games: Better together